Stock FBIO FORTRESS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.72 USD 0.00% Intraday chart for Fortress Biotech, Inc. -1.71% -42.86%
Apr. 03 North American Morning Briefing : Powell Awaited -2- DJ
Apr. 02 Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
AQ
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
AQ
Avenue Therapeutics Announces Reverse Stock Split
AQ
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024
AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
AQ
Fortress Biotech to Participate in 36th Annual ROTH Conference
AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
AQ
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
AQ
Lindsay Rosenwald̢۪s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
AQ
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
AQ
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy
AQ
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
AQ
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics
AQ
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FBIO Stock
  4. News Fortress Biotech, Inc.
  5. Press Releases